Canaccord lowered the firm’s price target on Zimmer Biomet to $131 from $150 and keeps a Hold rating on the shares. The firm updated its model and adjusted numbers to fall at the low end of guidance and are remaining conservative.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZBH:
- Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2023
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
- Zimmer Biomet price target raised to $125 from $120 at Morgan Stanley
- Zimmer Biomet price target lowered to $140 from $160 at JMP Securities
- Zimmer Biomet management to meet with BTIG